A Phase 2 interventional study of AT-527 and Placebo in COVID-19, sponsored by Atea Pharmaceuticals, Inc.. Terminated at 37 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-09.
Sponsored by Atea Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 677th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 343rd registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Atea Pharmaceuticals, Inc. is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 4 (16%) have results posted.
Atea Pharmaceuticals, Inc. has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to evaluate the safety, tolerability, antiviral activity and efficacy of AT-527 in adult subjects ≥18 years of age with moderate COVID-19 and risk factors for poor outcomes (such as obesity (BMI>30), hypertension, diabetes or asthma). Eligible subjects will be randomized to blinded AT-527 (nucleotide analog) tablets or matching placebo tablets to be administered orally for 5 days. Part A will evaluate an AT-527 dose of 550 mg BID and Part B will evaluate a second dose of AT-527 (1100 mg BID). Local supportive standard of care (SOC) will be allowed for all subjects. Efficacy, antiviral activity and safety observations will be compared for treatment with active AT-527 tablets vs. placebo tablets.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A
Drug: AT-527
Part A
Other: Placebo
Part B
Drug: AT-527
Part B
Other: Placebo
One 550 mg tablet of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
One placebo tablet administered every \~12 hours (twice a day) for a total of 5 days
Two 550 mg tablets of AT-527 administered every \~12 hours (twice a day) for a total of 5 days
Two placebo tablets administered every \~12 hours (twice a day) for a total of 5 days
Proportions (Active vs. Placebo) of Subjects With Progressive Respiratory Insufficiency (PRI) on or Before Day 14.
Progressive respiratory insufficiency defined as a ≥ 2-tier increase in respiratory support methods required to maintain satisfactory oxygenation (SpO2 ≥ 93%), using the 6-tier hierarchical scale of respiratory support methods, within the 14-day study period. Level 1:Normal oxygenation on room air (SpO2 ≥93), no need for supplemental O2 Level 2:Persistent hypoxemia on room air (SpO2 \<93) with requirement for low-level supplemental O2 by nasal cannula/mask (up to 2L/min) to maintain SpO2 ≥93 Level 3:Requirement for higher levels of passive supplemental O2 by nasal cannula or mask (≥2 L/min) to maintain SpO2 ≥93 Level 4:Requirement for oxygenation by positive-pressure devices Level 5:Required invasive respiratory support (intubated mechanical ventilation or ECMO) Level 6:Death
Time frame: Day 14
Change From Baseline in Amount of SARS-CoV-2 Virus RNA by Nasopharyngeal Swab
Change in the viral load as measured by swab of the upper part of the pharynx.
Time frame: Through Day 14
| Milestone | AT-527 - 550 mg BID | Placebo for 550 mg BID | AT-527 - 1100 mg BID | Placebo for 1100 mg BID |
|---|---|---|---|---|
| Started | 41 | 40 | 0 | 2 |
| Completed | 37 | 37 | 0 | 1 |
| Not completed | 4 | 3 | 0 | 1 |
Progressive respiratory insufficiency defined as a ≥ 2-tier increase in respiratory support methods required to maintain satisfactory oxygenation (SpO2 ≥ 93%), using the 6-tier hierarchical scale of respiratory support methods, within the 14-day study period. Level 1:Normal oxygenation on room air (SpO2 ≥93), no need for supplemental O2 Level 2:Persistent hypoxemia on room air (SpO2 \<93) with requirement for low-level supplemental O2 by nasal cannula/mask (up to 2L/min) to maintain SpO2 ≥93 Level 3:Requirement for higher levels of passive supplemental O2 by nasal cannula or mask (≥2 L/min) to maintain SpO2 ≥93 Level 4:Requirement for oxygenation by positive-pressure devices Level 5:Required invasive respiratory support (intubated mechanical ventilation or ECMO) Level 6:Death
| Participants | AT-527 - 550 mg BID | Placebo for 550 mg BID | AT-527 - 1100 mg BID | Placebo for 1100 mg BID |
|---|---|---|---|---|
| Proportions (Active vs. Placebo) of Subjects With Progressive Respiratory Insufficiency (PRI) on or Before Day 14. | 3 | 4 | — | 0 |
Change in the viral load as measured by swab of the upper part of the pharynx.
| log10 copies/mL | AT-527 - 550 mg BID | Placebo for 550 mg BID | AT-527 - 1100 mg BID | Placebo for 1100 mg BID |
|---|---|---|---|---|
| Change from baseline to Day 2 | -0.55 ± 1.175 | -0.02 ± 1.838 | — | -1.37 ± 1.57 |
| Change from baseline to Day 5 | -1.00 ± 1.316 | -0.80 ± 1.853 | — | -2.51 ± 0.66 |
| Change from baseline to Day 8 | -1.64 ± 1.534 | -1.38 ± 1.281 | — | -3.78 ± 1.39 |
| Change from baseline to Day 10 | -1.72 ± 1.734 | -2.26 ± 1.452 | — | -4.78 ± 2.13 |
| Change from baseline to Day 12 | -2.13 ± 2.065 | -2.08 ± 1.584 | — | -4.78 ± 2.13 |
| Change from baseline to Day 14 | -2.61 ± 1.873 | -2.26 ± 1.747 | — | -4.13 ± 1.21 |
Collected over 28 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AT-527 - 550 mg BID | 0/40 (0%) | 5/40 (12.5%) | 24/40 (60%) |
| Placebo for 550 mg BID | 2/40 (5%) | 3/40 (7.5%) | 23/40 (57.5%) |
| AT-527 - 1100 mg BID | — | — | — |
| Placebo for 1100 mg BID | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| Event | AT-527 - 550 mg BID | Placebo for 550 mg BID | AT-527 - 1100 mg BID | Placebo for 1100 mg BID |
|---|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/40 | 0/40 | — | 1/2 |
| Oxygen saturation decreasedInvestigations | 2/40 | 1/40 | — | 0/2 |
| Abdominal abscessInfections and infestations | 1/40 | 0/40 | — | 0/2 |
| Acute kidney injuryRenal and urinary disorders | 0/40 | 1/40 | — | 0/2 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/40 | 0/40 | — | 0/2 |
| COVID-19 pneumoniaInfections and infestations | 0/40 | 1/40 | — | 0/2 |
| Haemodynamic instabilityVascular disorders | 0/40 | 1/40 | — | 0/2 |
| Hyperglycaemic hyperosmolar nonketotic syndromeMetabolism and nutrition disorders | 1/40 | 0/40 | — | 0/2 |
| PneumoniaInfections and infestations | 0/40 | 1/40 | — | 0/2 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/40 | 1/40 | — | 0/2 |
| Event | AT-527 - 550 mg BID | Placebo for 550 mg BID | AT-527 - 1100 mg BID | Placebo for 1100 mg BID |
|---|---|---|---|---|
| UrticariaSkin and subcutaneous tissue disorders | 0/40 | 0/40 | — | 1/2 |
| HepatitisHepatobiliary disorders | 0/40 | 0/40 | — | 1/2 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/40 | 0/40 | — | 1/2 |
| N-terminal prohormone brain natriuretic peptide increasedInvestigations | 0/40 | 0/40 | — | 1/2 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/40 | 0/40 | — | 1/2 |
| Blood triglycerides increasedInvestigations | 6/40 | 6/40 | — | 0/2 |
| Alanine aminotransferase increasedInvestigations | 3/40 | 6/40 | — | 0/2 |
| Blood cholesterol increasedInvestigations | 5/40 | 2/40 | — | 0/2 |
| Aspartate aminotransferase increasedInvestigations | 2/40 | 3/40 | — | 0/2 |
| DiarrhoeaGastrointestinal disorders | 2/40 | 3/40 | — | 0/2 |
Intent-to-treat
| Age, Continuous(years) | AT-527 - 550 mg BID | Placebo for 550 mg BID | AT-527 - 1100 mg BID | Placebo for 1100 mg BID | Total |
|---|---|---|---|---|---|
| Mean | 54.3 ± 11.07 | 57.4 ± 8.33 | — | 33.5 ± 20.5 | 55.8 ± 9.88 |
| Sex: Female, Male(Participants) | AT-527 - 550 mg BID | Placebo for 550 mg BID | AT-527 - 1100 mg BID | Placebo for 1100 mg BID | Total |
|---|---|---|---|---|---|
| Female | 19 | 25 | — | 2 | 46 |
| Male | 22 | 15 | — | 0 | 37 |
| Race (NIH/OMB)(Participants) | AT-527 - 550 mg BID | Placebo for 550 mg BID | AT-527 - 1100 mg BID | Placebo for 1100 mg BID | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | — | 0 | 0 |
| Asian | 2 | 4 | — | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | — | 0 | 0 |
| Black or African American | 6 | 3 | — | 0 | 9 |
| White | 29 | 32 | — | 2 | 63 |
| More than one race | 2 | 1 | — | 0 | 3 |
| Unknown or Not Reported | 2 | 0 | — | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2020 to primary completion in Jan 2022, 19 months.
Results were first posted in Mar 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bemnifosbuvir